

Princy N Kumar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5264712/publications.pdf>

Version: 2024-02-01

59
papers

2,723
citations

567281
15
h-index

265206
42
g-index

60
all docs

60
docs citations

60
times ranked

4310
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 632.	7.4	803
2	Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. New England Journal of Medicine, 2021, 385, 1382-1392.	27.0	534
3	Highly Active Antiretroviral Therapy Decreases Mortality and Morbidity in Patients with Advanced HIV Disease. Annals of Internal Medicine, 2001, 135, 17.	3.9	516
4	Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. New England Journal of Medicine, 2018, 379, 645-654.	27.0	162
5	Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence. Clinical Infectious Diseases, 2018, 67, 649-656.	5.8	143
6	Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHT study. Lancet HIV, the, 2020, 7, e740-e751.	4.7	58
7	A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load. Clinical Infectious Diseases, 2022, 75, e440-e449.	5.8	46
8	Persistent Oxidative Stress and Inflammasome Activation in CD14 ^{high} CD16a ⁺ Monocytes From COVID-19 Patients. Frontiers in Immunology, 2021, 12, 799558.	4.8	44
9	Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC. Clinical Infectious Diseases, 2016, 63, 836-843.	5.8	37
10	Bartonella Endocarditis and Pauci-Immune Glomerulonephritis. Infectious Diseases in Clinical Practice, 2016, 24, 254-260.	0.3	35
11	The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1. AIDS Research and Human Retroviruses, 2016, 32, 636-647.	1.1	34
12	Evolocumab in HIV-Infected Patients With Dyslipidemia. Journal of the American College of Cardiology, 2020, 75, 2570-2584.	2.8	30
13	Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, 801-805.	2.1	25
14	Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus. Open Forum Infectious Diseases, 2021, 8, ofab537.	0.9	19
15	A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study). AIDS Research and Therapy, 2009, 6, 3.	1.7	18
16	Low CD4 nadir linked to widespread cortical thinning in adults living with HIV. Neurolmage: Clinical, 2020, 25, 102155.	2.7	18
17	Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 86-95.	2.1	15
18	Safety and Efficacy of Tocilizumab 4 or 8Âmg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial. Open Forum Infectious Diseases, 2022, 9, ofab608.	0.9	14

#	ARTICLE	IF	CITATIONS
19	Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials. <i>Clinical Infectious Diseases</i> , 2016, 63, 268-280.	5.8	13
20	Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. <i>Aids</i> , 2021, 35, 1061-1072.	2.2	13
21	Activation of Complement Components on Circulating Blood Monocytes From COVID-19 Patients. <i>Frontiers in Immunology</i> , 2022, 13, 815833.	4.8	11
22	Depression is associated with hippocampal volume loss in adults with HIV. <i>Human Brain Mapping</i> , 2021, 42, 3750-3759.	3.6	9
23	Cancer Incidence and Cancer Screening Practices Among a Cohort of Persons Receiving HIV Care in Washington, DC. <i>Journal of Community Health</i> , 2021, 46, 75-85.	3.8	9
24	“I feel empowered”: women’s perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain. <i>Culture, Health and Sexuality</i> , 2020, 23, 1-13.	1.8	8
25	IL-27 induces IFN/STAT1-dependent genes and enhances function of TIGIT+ HIVGag-specific T cells. <i>IScience</i> , 2022, 25, 103588.	4.1	8
26	Connectome-based prediction of global cognitive performance in people with HIV. <i>NeuroImage: Clinical</i> , 2021, 30, 102677.	2.7	7
27	Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHT Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0175121.	3.2	7
28	Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics. <i>American Heart Journal</i> , 2020, 220, 203-212.	2.7	6
29	Comorbidity and comedication burden among people living with HIV in the United States. <i>Current Medical Research and Opinion</i> , 2022, 38, 1443-1450.	1.9	6
30	Forty-eight-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1. <i>Open Forum Infectious Diseases</i> , 2017, 4, S38-S39.	0.9	5
31	A Phase I, Randomized, Controlled Clinical Study of CC-11050 in People Living With HIV With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRDITE). <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz246.	0.9	5
32	Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy. , 2020, 8, e000898.		3
33	1060. Pritelivir in Immunocompromised Patients with Mucocutaneous Acyclovir-Resistant Herpes Simplex Virus-Infections – First Case Series. <i>Open Forum Infectious Diseases</i> , 2021, 8, S622-S623.	0.9	3
34	The impacts of HIV infection, age, and education on functional brain networks in adults with HIV. <i>Journal of NeuroVirology</i> , 2022, 28, 265-273.	2.1	3
35	2497. Women’s Perspectives on and Experiences with Long-acting Injectable Anti-retroviral Therapy in the United States and Spain: the Potential Role of Gender in Patient Preferences. <i>Open Forum Infectious Diseases</i> , 2019, 6, S866-S866.	0.9	2
36	A disease disregards anatomical planes: actinomycosis and an intrauterine device. <i>Lancet, The</i> , 2020, 396, 1766.	13.7	2

#	ARTICLE	IF	CITATIONS
37	The Cost-Effectiveness and Budget Impact of Ibalizumab-uyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States. <i>Pharmacoeconomics</i> , 2021, 39, 421-432.	3.3	2
38	Integrase Inhibitor Prescribing Disparities in the DC and Johns Hopkins HIV Cohorts. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab338.	0.9	2
39	639. Time to Recurrence of <i>Clostridioides difficile</i> Infection (rCDI) is Rapid Following Completion of Standard of Care Antibiotics: Results from ECOSPOR-III, a Phase 3 Double-Blind, Placebo-Controlled Randomized Trial of SER-109, an Investigational Microbiome Therapeutic. <i>Open Forum Infectious Diseases</i> , 2021, 8, S422-S422.	0.9	2
40	544. Pharmacokinetic Profile of Ibalizumab From a Phase 3 Trial. <i>Open Forum Infectious Diseases</i> , 2018, 5, S202-S202.	0.9	1
41	Healthcare Worker With Large Vessel Acute Ischemic Stroke Likely Related to Mild SARS-CoV-2 Infection. <i>Neurohospitalist</i> , The, 2020, 12, 194187442096684.	0.8	1
42	The Role of Inflammation and Immune Activation on Circulating Endothelial Progenitor Cells in Chronic HIV Infection. <i>Frontiers in Immunology</i> , 2021, 12, 663412.	4.8	1
43	IL-27 Modulates the Cytokine Secretion in the T Cellâ€œOsteoclast Crosstalk During HIV Infection. <i>Frontiers in Immunology</i> , 2022, 13, 818677.	4.8	1
44	Prevalence of Multidrug-Resistant Organisms Using an Antibiotic Resistant Gene Assay at a Tertiary Care Center. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
45	Assessing Carbapenemase Resistant Enterobacteriaceae Prevalence Using a Combined Antibiotic Resistance Gene Assay and Surveillance Cultures in Hospitalized Patients. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
46	Primary Efficacy Endpoint and Safety Results of Ibalizumab in a Phase 3 Study of Heavily Treatment-Experienced Patients With Multidrug-Resistant Human Immunodeficiency Virus-1 Infection. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
47	[ICâ€œ46]: TASKâ€œFREE MAGNETIC RESONANCE BRAIN IMAGING DISTINGUISHES ALZHEIMER's DISEASE FROM HIVâ€œDISEASE VIA SUPPORT VECTOR MACHINE CLASSIFICATION. <i>Alzheimer's and Dementia</i> , 2017, 13, P111.	0.8	0
48	[P1â€œ373]: TASKâ€œFREE MAGNETIC RESONANCE BRAIN IMAGING DISTINGUISHES ALZHEIMER's DISEASE FROM HIVâ€œDISEASE VIA SUPPORT VECTOR MACHINE CLASSIFICATION. <i>Alzheimer's and Dementia</i> , 2017, 13, P404.	0.8	0
49	2492. Differences between Individuals Currently Taking Integrase Inhibitor (INSTI)-based Therapy and Those Not Taking INSTIs in the Era of INSTIs as Recommended First-line Therapy. <i>Open Forum Infectious Diseases</i> , 2019, 6, S864-S865.	0.9	0
50	2786. The Role of Respiratory Panel PCR in Decreasing Antibiotic Exposure in Patients Diagnosed With a Respiratory Viral Infection. <i>Open Forum Infectious Diseases</i> , 2019, 6, S984-S984.	0.9	0
51	41224 REDUCED FRONTOSTRIATAL FUNCTIONAL CONNECTIVITY IN 41- TO 70-YEAR-OLD ADULTS WITH HIV. <i>Journal of Clinical and Translational Science</i> , 2021, 5, 13-13.	0.6	0
52	1008. Disease Severity Impact on Long-Term Virologic Response to Ibalizumab in Expanded Access Protocol (TMB-311). <i>Open Forum Infectious Diseases</i> , 2020, 7, S532-S532.	0.9	0
53	1046. Week 48 Outcomes from the BRAAVE 2020 Study: A Randomized Switch to B/F/TAF in African American Adults with HIV. <i>Open Forum Infectious Diseases</i> , 2020, 7, S552-S553.	0.9	0
54	466. SARS-CoV-2 Diagnosis And Point Prevalence in a Non-Cohorted Tertiary Care Center. <i>Open Forum Infectious Diseases</i> , 2020, 7, S299-S300.	0.9	0

#	ARTICLE	IF	CITATIONS
55	509. Clinical Characteristics and Outcomes in Patients Infected with SARS-CoV-2 Treated with Remdesivir, Tocilizumab, and/or Dexamethasone at a Mid-Atlantic Hospital Consortium. Open Forum Infectious Diseases, 2021, 8, S356-S357.	0.9	0
56	832. Body Mass Index and Quality of Life in People Living With HIV. Open Forum Infectious Diseases, 2021, 8, S508-S508.	0.9	0
57	297. Infectious Complications Associated with Tocilizumab Use in Patients Infected with SARS-CoV-2 at a Mid-Atlantic Hospital Consortium. Open Forum Infectious Diseases, 2021, 8, S256-S256.	0.9	0
58	286. Infectious Complications and Antimicrobial Utilization in Hospitalized Patients with COVID-19. Open Forum Infectious Diseases, 2021, 8, S249-S249.	0.9	0
59	Cingulate transcranial direct current stimulation in adults with HIV. PLoS ONE, 2022, 17, e0269491.	2.5	0